Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Dermira, Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States. The company?s late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04, a anticholinergic product that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01, a sebum inhibitor, which has completed a Phase IIa clinical trial for the treatment of acne. Its early-stage programs in preclinical development include DRM02, an inhibitor of phosphodiesterase-4 for the treatment of inflammatory skin diseases; and DRM05, a photodynamic therapy for the treatment of acne. Dermira, Inc. has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-17.27%||ROE||-20.31%||ROI|
|Current Ratio||10.38||Quick Ratio||Long Term Debt/Equity||0.02||Debt Ratio||0.09|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||40 K||Cash From Investing Activities||1.86 M||Cash From Operating Activities||-5.12 M||Gross Profit|
|Net Profit||-14.04 M||Operating Profit||-14.23 M||Total Assets||165.61 M||Total Current Assets||124.49 M|
|Total Current Liabilities||12 M||Total Debt||1.94 M||Total Liabilities||24.75 M||Total Revenue|
|High 52 week||14.82||Low 52 week||6.19||Last close||10.5||Last change||-0.47%|
|RSI||36.61||Average true range||0.59||Beta||1.06||Volume||98.87 K|
|Simple moving average 20 days||-2.75%||Simple moving average 50 days||-9%||Simple moving average 200 days||4.07%|
|Performance Week||-1.69%||Performance Month||-5.66%||Performance Quart||35.14%||Performance Half||3.55%|
|Performance Year||-2.33%||Performance Year-to-date||46.04%||Volatility daily||3.35%||Volatility weekly||7.5%|
|Volatility monthly||15.36%||Volatility yearly||53.23%||Relative Volume||231.19%||Average Volume||2.15 M|
|New High||New Low|
2019-09-10 12:24:45 | How Much Are Dermira, Inc. NASDAQ:DERM Insiders Spending On Buying Shares?
2019-08-29 16:05:00 | Dermira to Participate in Upcoming Investor Conferences
2019-08-20 00:15:17 | Dermira Inc DERM CEO & Chairman of the Board Thomas G Wiggans Bought $199,998 of Shares
2019-08-08 12:00:08 | Edited Transcript of DERM earnings conference call or presentation 7-Aug-19 8:30pm GMT
2019-08-07 19:45:11 | Dermira DERM Reports Q2 Loss, Tops Revenue Estimates
2019-08-07 16:05:00 | Dermira Reports Second Quarter 2019 Financial Results and Provides Corporate Update
2019-07-29 10:34:02 | Earnings Preview: Dermira DERM Q2 Earnings Expected to Decline
2019-07-25 13:03:48 | 5 Biotech Stocks to Buy for Blockbuster Potential
2019-07-24 15:15:48 | Should You Be Pleased About The CEO Pay At Dermira, Inc.'s NASDAQ:DERM
2019-07-01 09:15:01 | Stocks Soar 7% in June
2019-06-11 16:00:00 | Dermira to Present at the Raymond James Life Sciences and MedTech Conference
2019-06-11 08:05:48 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-06-10 08:05:02 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-06-06 13:34:00 | Dermira Advances on Analyst Upgrade to Buy
2019-06-06 08:05:15 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-06-04 08:03:27 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-05-08 15:24:17 | Dermira DERM Q1 2019 Earnings Call Transcript
2019-05-08 11:13:10 | Did You Manage To Avoid Dermira's NASDAQ:DERM Painful 63% Share Price Drop?
2019-05-08 01:11:11 | Edited Transcript of DERM earnings conference call or presentation 7-May-19 8:30pm GMT
2019-05-07 19:25:11 | Dermira DERM Reports Q1 Loss, Lags Revenue Estimates
2019-05-07 18:19:15 | Dermira: 1Q Earnings Snapshot
2019-05-07 16:05:00 | Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update
2019-05-07 08:03:19 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-04-25 10:34:02 | Dermira DERM May Report Negative Earnings: Know the Trend Ahead of Q1 Release
2019-04-17 09:15:01 | NASDAQ Back Above 8,000
2019-04-08 17:06:00 | Here's Why Dermira Shot Up 62% in March
2019-04-03 16:05:00 | Dermira to Present at the 18th Annual Needham Healthcare Conference
2019-04-01 14:09:21 | Does The Dermira, Inc. NASDAQ:DERM Share Price Fall With The Market?
2019-03-28 08:02:07 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-03-26 08:21:58 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-03-20 10:28:02 | Dermira DERM Catches Eye: Stock Jumps 12%
2019-03-19 19:36:06 | Dermira Prices $130.0 Million Public Offering of Common Stock
2019-03-19 16:00:00 | Why Dermira Stock Jumped Again Today
2019-03-19 10:52:02 | Company News For Mar 19, 2019
2019-03-19 08:31:14 | See what the IHS Markit Score report has to say about Dermira Inc.
2019-03-19 06:06:00 | Can Dermira Stock Keep Soaring?
2019-03-18 16:30:24 | Dermira Announces Proposed Public Offering of Common Stock
2019-03-18 14:22:58 | Why Dermira Stock Is Soaring More than 80% Today
2019-03-18 12:31:42 | Dermira News: Why DERM Stock Is Skyrocketing Today
2019-03-18 12:14:00 | Why Dermira's Shares Are Doubling Today
2019-03-18 11:15:37 | Dermira Investors Get 100% One-Day Payoff a Year After Acne Flop
2019-03-18 10:00:00 | Dermira Shares Rocket After Successful Phase II Eczema Treatment Study
2019-03-18 09:53:04 | Why Dermira Shares Are Shooting Higher After Last Year's Disappointment
2019-03-18 07:24:00 | Dermira shares soar 83% premarket on news of positive trial of dermatitis treatment